The prototype phosphodiesterase type 5 inhibitor which did not predict the interesting properties of its more selective successors. Long used with weak evidence base, perhaps because of its half life in peripheral vascular disease, it has fair evidence of effectiveness in secondary prevention of ischaemic stroke, and is useful in cardiac stress testing.
- Antiplatelet agent
- Vasodilator increasing cardiac workload (iv)
Oral - Usual dose is modified release 200mg bd with low dose aspirin in secondary stroke prevention.
Cautions and Interactions